Quartz·1 min read·medium
Q32 Bio stock soared after its alopecia drug cleared a key clinical bar
✦AI Summary
Biotech firm Q32 Bio reported positive Phase 2a clinical trial results for its alopecia drug, bempikibart. The treatment achieved a 35.3% reduction in hair loss, prompting the company to plan for a registration-directed program by 2027.
The biotech's Phase 2a study of bempikibart showed a 35.3% mean reduction in hair loss scores, with the company planning a registration-directed program by early 2027
businesshealth
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in